CORDELIANCT06310356
Continuous Glucose Monitoring for Women With Gestational Diabetes
StatusActive, Not Recruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.
All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗
- Minor Enrollment closed, study ongoing
- Minor Study sites: 14 to 16
- Collaborators: 14 to 16
- Notable Primary completion date: Sep 2025 to Feb 2027
- Study completion date: Feb 2027 to Aug 2027
- Minor Site details revised at 5 of 14 sitesv6
- Minor Start date changed from estimate of Nov 2024 to Nov 18, 2024
- Site details revised at 1 of 14 sites
Show 3 earlier versionsHide 3 earlier versions
- Notable Trial status: Not Yet Recruiting to Recruiting
- Start date: Sep 2024 to Nov 2024
- Study sites: 15 to 14
- Minor Study sites: 17 to 15
- Collaborators: 16 to 14
- Minor Secondary endpoints revised (56)v2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
A composite of pregnancy outcomes
Timeframe: at delivery
Secondary (45)
Main secondary outcomes: Hierarchical win ratio analysis
Main secondary outcomes: Time in range
Main secondary outcomes: Time above range
Main secondary outcomes: gestational weight gain
Main secondary outcomes: Small-for-gestational age infant
Show 40 moreShow less
Exploratory glycemic targets (mg/dL or mmol/L)
Mean glucose
Glucose management indicator (GMI)
HbA1c
area under the curve (AUC)
Glycemic variability
timing of start insulin treatment
mean insulin dose
rate of postpartum hemorrhage
rate of macrosomia
rate of baby >4.5Kg
rate of cesarean section
rate of instrumental delivery
rate of perineal inury
rate of labor inductions
rate of preeclamspia
rate of gestational hypertension
rate of fetal malformation
rate of miscarriage
rate of polycythemia
LGA and SGA [SPE rapport 2009],
rate of neonatal hypoglycemia
Treatment satisfaction
Quality of life based on Short Form (SF-36) score
dietary intake
Physical activity
fear for hypoglycaemia
fear for hyperglycaemia
symptoms of depression
symptoms of anxiety
user-friendliness of CGM
user-friendliness of CGM compared to oral glucose tolerance test (OGTT)
duration of breastfeeding
rate of hypercholesterolemia
night glucose time in range between 70-180mg/dl
day glucose time in range between 70-180mg/dl
day glucose time in range <70mg/dl
night glucose time in range <70mg/dl
night glucose time in range >180mg/dl
day glucose time in range >180mg/dl
Arms and interventions
continuous glucose monitoringExperimental
continuous use of realtime-continuous glucose monitoring with Freestyle Libre 3
self monitoring of blood glucose with glucometerActive comparator
self monitoring of blood glucose with glucometer, at least 2 days per week if treated with lifestyle and daily if additional treatment with insulin is started
Devices: Freestyle Libre 3, Glucometer
Sites
16 sites in 2 countries
Belgium 14, Australia 2